# Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI

> **NCT03677336** · PHASE4 · COMPLETED · sponsor: **CRG UZ Brussel** · enrollment: 30 (actual)

## Conditions studied

- Infertility, Female
- Infertility
- Genital Diseases, Male
- Genital Diseases, Female
- Progesterone
- Dydrogesterone
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Physiological Effects of Drugs
- Progestins

## Interventions

- **DRUG:** Dydrogesterone Oral Tablet
- **DRUG:** Micronized progesterone
- **DRUG:** Placebo Dydrogesterone oral tablet
- **DRUG:** Placebo Micronized progesterone

## Key facts

- **NCT ID:** NCT03677336
- **Lead sponsor:** CRG UZ Brussel
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-01
- **Primary completion:** 2020-08-24
- **Final completion:** 2020-08-24
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03677336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03677336, "Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03677336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*